These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31055767)

  • 1. Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis.
    de Souza Lima Bitar Y; Neto MG; Filho JAL; Pereira LV; Travassos KSO; Akrami KM; Roever L; Duraes AR
    Drugs R D; 2019 Jun; 19(2):117-126. PubMed ID: 31055767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
    Renda G; Ricci F; Giugliano RP; De Caterina R
    J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.
    Malik AH; Yandrapalli S; Aronow WS; Panza JA; Cooper HA
    Heart; 2019 Sep; 105(18):1432-1436. PubMed ID: 31203254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.
    Caldeira D; David C; Costa J; Ferreira JJ; Pinto FJ
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):111-118. PubMed ID: 28950374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
    Briasoulis A; Inampudi C; Akintoye E; Alvarez P; Panaich S; Vaughan-Sarrazin M
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review.
    Fu Y; Zhu W; Zhou Y; Chen H; Yan L; He W
    Am J Cardiovasc Drugs; 2020 Apr; 20(2):139-147. PubMed ID: 31485852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
    Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
    Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bitar YSL; Duraes AR; Roever L; Gomes Neto M; Lins-Kusterer L; Bocchi EA
    Front Cardiovasc Med; 2021; 8():712585. PubMed ID: 34631818
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis.
    Barbarawi M; Barbarawi O; Corcoran J; Obeidat K; Al-Abdouh A; Mhanna M; Al Kasasbeh M; Pickett CC
    Curr Probl Cardiol; 2022 Nov; 47(11):101346. PubMed ID: 35932849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials.
    Patti G; Di Gioia G; Cavallari I; Nenna A
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 28029216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
    Ruff CT; Giugliano RP; Braunwald E; Hoffman EB; Deenadayalu N; Ezekowitz MD; Camm AJ; Weitz JI; Lewis BS; Parkhomenko A; Yamashita T; Antman EM
    Lancet; 2014 Mar; 383(9921):955-62. PubMed ID: 24315724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Previous Stroke: A Systematic Review and Meta-Analysis.
    Shi M; Liu L; Wafa H; Curcin V; Wang Y
    Neuroepidemiology; 2024; 58(1):1-14. PubMed ID: 37848006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis.
    Liao XZ; Fu YH; Ma JY; Zhu WG; Yuan P
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):391-399. PubMed ID: 32206988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
    Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis.
    Bai Y; Guo SD; Deng H; Shantsila A; Fauchier L; Ma CS; Lip GYH
    Age Ageing; 2018 Jan; 47(1):9-17. PubMed ID: 28985259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.